Method for detecting tryptophan impurity A in compound amino acid injection and application
Through high-performance liquid chromatography, the interference problem of tryptophan impurity A detection in compound amino acid injection was solved, and quantitative detection with high sensitivity and high precision was achieved, which improved the safety of the product.
Patent Information
- Application Number
- CN202411121805.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-12
Smart Images

Figure CN118937525A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of analytical chemistry, and in particular to a method for detecting tryptophan impurity A in a compound amino acid injection and an application thereof. Background Art
[0002] Compound amino acid injection is a common parenteral nutrition injection with a wide range of clinical applications. Due to its complex composition, especially the unstable tryptophan, which is easily oxidized and degraded to produce impurities, resulting in unstable product quality, which in turn affects the patient's medication safety. Therefore, it is necessary to study the tryptophan impurities. Impurity A is one of its main process impurities, and its structural formula is as follows:
[0003]
[0004] In the existing literature, the EP contains a detection method for related substances of tryptophan raw materials, but this detection method is only applicable to the detection of tryptophan raw materials, while the compound amino acid injection contains more than 10 or even more amino acids, with complex ingredients, which interferes with the detection of tryptophan impurity A and has poor method specificity. Therefore, it is necessary to establish a separate method for the detection of tryptophan impurity A in order to effectively detect the tryptophan impurity content in the compound amino acid preparation. Summary of the invention
[0005] The present invention aims to solve the technical problems that the prior art has interference in the detection of tryptophan impurity A and the method has poor specificity. The purpose is to provide a detection method and application of tryptophan impurity A in compound amino acid injection, which has the advantages of strong specificity, high sensitivity, good precision, strong durability, etc., and can qualitatively or quantitatively detect tryptophan impurity A in compound amino acid injection, thereby improving the safety of clinical use of relevant compound amino acid injection.
[0006] The present invention is achieved through the following technical solutions:
[0007] The first object of the present invention is to provide a method for detecting tryptophan impurity A in a compound amino acid injection, using high performance liquid chromatography to detect tryptophan impurity A in the compound amino acid injection, using a chromatographic column with phenylsilane bonded silica gel as a filler, using a mobile phase for gradient elution, and using an ultraviolet detector for detection;
[0008] The mobile phase consists of mobile phase A and mobile phase B, wherein mobile phase A is a mixed solution of methanol and phosphate buffer solution; mobile phase B is an acetonitrile aqueous solution.
[0009] Furthermore, the mobile phase A is a mixed solution of methanol and a phosphate buffer solution with a concentration of 0.01 mol / L to 0.03 mol / L.
[0010] Furthermore, the phosphate in the phosphate buffer solution in the mobile phase A includes sodium dihydrogen phosphate and / or potassium dihydrogen phosphate.
[0011] Furthermore, the volume ratio of the phosphate buffer solution to methanol in the mobile phase A is (90:10) to (95:5).
[0012] Furthermore, the pH range of the mobile phase A is 4.0 to 4.5.
[0013] Furthermore, the volume ratio of acetonitrile to water in the mobile phase B is (40:60) to (60:40).
[0014] Furthermore, the chromatographic conditions are as follows: detection wavelength of 200 nm to 230 nm, mobile phase flow rate of 0.6 mL / min to 0.8 mL / min, injection volume of 50 μL to 150 μL, and column temperature of 30° C. to 40° C.
[0015] Furthermore, the detection wavelength is 220 nm, the mobile phase flow rate is 0.7 mL / min, the injection volume is 100 μL, and the column temperature is 35° C.
[0016] Furthermore, the conditions of the gradient elution are:
[0017] Time: 0 min, 68-72% mobile phase A, 28-32% mobile phase B;
[0018] Time: 15 min, 68-72% mobile phase A, 28-32% mobile phase B;
[0019] Time: 16 min, 0-2% mobile phase A, 98-100% mobile phase B;
[0020] Time: 35 min, 0-2% mobile phase A, 98-100% mobile phase B;
[0021] Time: 36 min, 68-72% mobile phase A, 28-32% mobile phase B;
[0022] Time: 45 min, 68-72% mobile phase A, 28-32% mobile phase B.
[0023] The second object of the present invention is to provide an application of the above detection method in detecting tryptophan impurity A in compound amino acid injection.
[0024] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0025] The present invention effectively improves the peak shape and separation of tryptophan impurity A by screening and optimizing the mobile phase ratio and chromatographic conditions such as pH, flow rate, column temperature, wavelength, etc., and realizes accurate quantitative detection of the impurity. The detection method has been verified by systematic methodology, has the advantages of strong specificity, high sensitivity, good precision, strong durability, etc., and can qualitatively or quantitatively detect tryptophan impurity A in compound amino acid injection, thereby improving the safety of clinical use of the relevant compound amino acid injection. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] In order to more clearly illustrate the technical solutions of the exemplary embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and should not be regarded as limiting the scope. For those of ordinary skill in the art, other relevant drawings can be obtained based on these drawings without creative work. In the drawings:
[0027] Figure 1 Schematic diagram of HPLC of impurity A reference solution;
[0028] Figure 2 Schematic diagram of HPLC of impurity A system suitability solution.
[0029] Figure 3 is a linear relationship diagram of impurity A in Example 2;
[0030] Figure 4 Schematic diagram of HPLC of the system suitability solution in Comparative Example 1. DETAILED DESCRIPTION
[0031] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments and drawings. The exemplary embodiments of the present invention and their description are only used to explain the present invention and are not intended to limit the present invention.
[0032] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.
[0033] The technical solution of the specific implementation mode of the present invention is:
[0034] A method for detecting tryptophan impurity A in a compound amino acid injection, comprising: using high performance liquid chromatography to detect tryptophan impurity A in the compound amino acid injection, using a chromatographic column with phenylsilane bonded silica gel as a filler, performing gradient elution with a mobile phase, and detecting with an ultraviolet detector;
[0035] The detection wavelength is 200nm to 230nm, for example, it can be 200, 205, 210, 215, 220, 225, 230nm and any range between any two values, preferably 215 to 225nm, and most preferably 220nm.
[0036] The flow rate of the mobile phase is 0.6 mL / min to 0.8 mL / min, for example, 0.6, 0.65, 0.7, 0.75, 0.8, preferably 0.65 to 0.75 mL / min, and most preferably 0.7 mL / min.
[0037] The injection volume is 50 μL to 150 μL, for example, it can be 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150 μL, preferably 80 to 120 μL, and the most preferred injection volume is 100 μL.
[0038] The column temperature is 30°C to 40°C, for example, 30, 32, 35, 38, or 40°C, and preferably the column temperature is 35°C.
[0039] Wherein, the mobile phase is composed of mobile phase A and mobile phase B. The mobile phase A is a mixed solution of methanol and a phosphate buffer solution with a concentration of 0.01 mol / L to 0.03 mol / L, preferably, the phosphate buffer solution concentration of the mobile phase A is 0.02 mol / L; the volume ratio of the phosphate buffer solution to methanol in the mobile phase A is (90:10) to (95:5), preferably, the volume ratio of the phosphate buffer solution to methanol in the mobile phase A is 92:8; the pH of the mobile phase A is 4.0 to 4.5, preferably, the pH of the mobile phase A is 4.3; the mobile phase A uses phosphoric acid to adjust the pH.
[0040] Adding an appropriate amount of methanol to the mobile phase A of the present invention can better maintain the life of the chromatographic column, shorten the running time, and keep the peak shape of impurity A better. On this basis, the peak shape of impurity A is better when the pH range is set to 4.0-4.5.
[0041] The mobile phase B is an acetonitrile aqueous solution. The volume ratio of acetonitrile to water in the mobile phase B is (40:60) to (60:40), and preferably, the volume ratio of acetonitrile to water in the mobile phase B is 50:50.
[0042] The conditions of the gradient elution are:
[0043] Time: 0 min, 68-72% mobile phase A, 28-32% mobile phase B;
[0044] Time: 15 min, 68-72% mobile phase A, 28-32% mobile phase B;
[0045] Time: 16 min, 0-2% mobile phase A, 98-100% mobile phase B;
[0046] Time: 35 min, 0-2% mobile phase A, 98-100% mobile phase B;
[0047] Time: 36 min, 68-72% mobile phase A, 28-32% mobile phase B;
[0048] Time: 45 min, 68-72% mobile phase A, 28-32% mobile phase B.
[0049] As a preferred embodiment, the present embodiment provides a method for detecting tryptophan impurity A in a compound amino acid injection, comprising: using high performance liquid chromatography, the chromatographic conditions comprising: using a chromatographic column with phenylsilane bonded silica gel as a filler, gradient elution with a mobile phase, detection with an ultraviolet detector, a detection wavelength of 220 nm, a mobile phase flow rate of 0.7 mL / min, an injection volume of 100 μl, and a column temperature of 35°C.
[0050] Wherein, the mobile phase consists of mobile phase A and mobile phase B. Mobile phase A: a mixed solution of methanol and phosphate buffer solution. The mobile phase A is a mixed solution of methanol and a phosphate buffer solution with a concentration of 0.02 mol / L; wherein the volume ratio of the phosphate buffer solution to methanol is 92:8. The phosphate of the phosphate buffer solution includes sodium dihydrogen phosphate and / or potassium dihydrogen phosphate, specifically sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium dihydrogen phosphate and potassium dihydrogen phosphate. The pH of the mobile phase A is 4.3, and the mobile phase A uses phosphoric acid to adjust the pH.
[0051] Mobile phase B: acetonitrile aqueous solution, wherein the volume ratio of acetonitrile to water in the mobile phase B is 50:50.
[0052] The conditions of the gradient elution are:
[0053] Time: 0 min, 70% mobile phase A, 30% mobile phase B;
[0054] Time: 15 min, 70% mobile phase A, 30% mobile phase B;
[0055] Time: 16 min, 0% mobile phase A, 100% mobile phase B;
[0056] Time: 35 min, 0% mobile phase A, 100% mobile phase B;
[0057] Time: 36 min, 70% mobile phase A, 30% mobile phase B;
[0058] Time: 45 min, 70% mobile phase A, 30% mobile phase B.
[0059] The specific embodiments of the present invention are as follows:
[0060] Among them, this product refers to compound amino acid injection (18AA-VII), provided by Sichuan Kelun Pharmaceutical Co., Ltd.
[0061] Example 1: Specificity experiment
[0062] A method for detecting tryptophan impurity A in a compound amino acid injection, comprising:
[0063] Reference substance stock solution: Take about 10 mg of tryptophan impurity A reference substance, accurately weigh, place in a 100 mL volumetric flask, dissolve with methanol-water (20:80), dilute to the scale, shake well, accurately measure 1 mL into a 100 mL volumetric flask, dilute to the scale with methanol-water (20:80), shake well, accurately measure 1 mL into a 10 mL volumetric flask, dilute to the scale with methanol-water (20:80), shake well.
[0064] Reference substance solution: Accurately measure 1 mL of reference substance stock solution, place it in the same 10 mL volumetric flask, dilute to the mark with methanol-water (20:80), and shake well.
[0065] Sensitivity solution: Accurately measure 4 mL of the tryptophan impurity A reference stock solution, place it in a 100 mL volumetric flask, add methanol-water (20:80) to dilute to the scale, and shake well.
[0066] System suitability solution: Accurately measure 8 mL of this product and place it in a 10 mL volumetric flask. Add 1 mL of the reference substance stock solution, dilute to the mark with methanol-water (20:80), and shake well.
[0067] Chromatographic conditions:
[0068] Column: kromasil Eternity-5-PhenylHexyl, 4.6 mm × 250 mm, 5 μm;
[0069] Mobile phase A: 0.02 mol / L potassium dihydrogen phosphate buffer (pH adjusted to 4.3 with phosphoric acid)-methanol (92:8);
[0070] Mobile phase B: acetonitrile-water (50:50);
[0071] Diluent: methanol-water (20:80);
[0072] Wavelength: 220nm;
[0073] Column temperature: 35°C;
[0074] Flow rate: 0.7 mL / min;
[0075] Injection volume: 100 μL;
[0076] The gradient elution conditions were as follows:
[0077] Time: 0 min, 70% mobile phase A, 30% mobile phase B;
[0078] Time: 15 min, 70% mobile phase A, 30% mobile phase B;
[0079] Time: 16 min, 0% mobile phase A, 100% mobile phase B;
[0080] Time: 35 min, 0% mobile phase A, 100% mobile phase B;
[0081] Time: 36 min, 70% mobile phase A, 30% mobile phase B;
[0082] Time: 45 min, 70% mobile phase A, 30% mobile phase B.
[0083] Detection method: Accurately measure the reference solution, sensitivity solution and system suitability solution respectively, inject them into the high performance liquid chromatograph for detection. The results are shown in Table 1.
[0084] Table 1. Results of the specificity survey
[0085]
[0086] It can be seen from Table 1 that the retention time of impurity A in the reference solution and the system suitability solution is basically the same. Figure 1 Schematic diagram of HPLC of impurity A reference solution. Figure 2 is a schematic diagram of HPLC for system suitability solution; Figure 2 It can be seen that in the system suitability solution, the separation degree between impurity A and the adjacent peak is 3.06, and the separation effect is good, indicating that the chromatographic conditions of the present invention can effectively separate tryptophan impurity A.
[0087] Example 2: Linearity and sensitivity experiments
[0088] A method for detecting tryptophan impurity A in a compound amino acid injection, comprising:
[0089] Reference substance stock solution: Take about 10 mg of tryptophan impurity A reference substance, accurately weigh it, put it in a 100 mL volumetric flask, dissolve it with methanol-water (20:80), dilute it to the scale, shake it well, accurately measure 1 mL into a 100 mL volumetric flask, dilute it to the scale with methanol-water (20:80), and shake it well.
[0090] Tryptophan impurity A linear solution: Accurately measure 2 mL of the tryptophan impurity A reference stock solution, place it in a 20 mL volumetric flask, dilute to the scale with methanol-water (20:80), and shake well.
[0091] The impurity A linear solution was taken to prepare linear solutions containing impurity A at concentrations of 0.00196 μg / mL, 0.00490 μg / mL, 0.00980 μg / mL, 0.01470 μg / mL, 0.01960 μg / mL, and 0.02940 μg / mL, respectively.
[0092] Chromatographic conditions:
[0093] Column: kromasil Eternity-5-PhenylHexyl, 4.6 mm × 250 mm, 5 μm;
[0094] Mobile phase A: 0.02 mol / L potassium dihydrogen phosphate buffer (pH adjusted to 4.3 with phosphoric acid)-methanol (92:8);
[0095] Mobile phase B: acetonitrile-water (50:50);
[0096] Diluent: methanol-water (20:80);
[0097] Wavelength: 220nm;
[0098] Column temperature: 35°C;
[0099] Flow rate: 0.7 mL / min;
[0100] Injection volume: 100 μL;
[0101] The gradient elution conditions were as follows:
[0102] Time: 0 min, 70% mobile phase A, 30% mobile phase B;
[0103] Time: 15 min, 70% mobile phase A, 30% mobile phase B;
[0104] Time: 16 min, 0% mobile phase A, 100% mobile phase B;
[0105] Time: 35 min, 0% mobile phase A, 100% mobile phase B;
[0106] Time: 36 min, 70% mobile phase A, 30% mobile phase B;
[0107] Time: 45 min, 70% mobile phase A, 30% mobile phase B.
[0108] Detection method: Accurately measure 6 linear solutions and quantitative limit solutions of different concentrations, inject them into high performance liquid chromatography for detection. The results are shown in Table 2 and the linear relationship diagram is shown in Figure 3 shown.
[0109] Table 2. Linearity and sensitivity investigation results
[0110]
[0111] As shown in Table 2, the linear equation correlation coefficient r reaches 0.9998, and the linear relationship is good. When the impurity A is at the quantitative limit concentration, the signal-to-noise ratio is greater than 10. This indicates that the sensitivity of tryptophan impurity A is high under the chromatographic conditions of the present invention.
[0112] Example 3: Precision Experiment
[0113] A method for detecting tryptophan impurity A in a compound amino acid injection, comprising:
[0114] Reference substance stock solution: Take about 10 mg of tryptophan impurity A reference substance, accurately weigh, place in a 100 mL volumetric flask, dissolve with methanol-water (20:80), dilute to the scale, shake well, accurately measure 1 mL into a 100 mL volumetric flask, dilute to the scale with methanol-water (20:80), shake well, accurately measure 1 mL into a 10 mL volumetric flask, dilute to the scale with methanol-water (20:80), shake well.
[0115] Reference substance solution: Accurately measure 1 mL of reference substance stock solution, place it in the same 10 mL volumetric flask, dilute to the mark with methanol-water (20:80), and shake well.
[0116] Test solution: Accurately measure 8 mL of the product, place it in a 10 mL volumetric flask, dilute to the scale with methanol-water (20:80), shake well, and obtain.
[0117] Test sample spike solution: Accurately measure 8 mL of the product and place it in a 10 mL volumetric flask. Add 1 mL of the reference stock solution and dilute to the mark with methanol-water (20:80) and shake well.
[0118] Chromatographic conditions:
[0119] Column: kromasil Eternity-5-PhenylHexyl, 4.6 mm × 250 mm, 5 μm;
[0120] Mobile phase A: 0.02 mol / L potassium dihydrogen phosphate buffer (pH adjusted to 4.3 with phosphoric acid)-methanol (92:8);
[0121] Mobile phase B: acetonitrile-water (50:50);
[0122] Diluent: methanol-water (20:80);
[0123] Wavelength: 220nm;
[0124] Column temperature: 35°C;
[0125] Flow rate: 0.7 mL / min;
[0126] Injection volume: 100 μL;
[0127] The gradient elution conditions were as follows:
[0128] Time: 0 min, 70% mobile phase A, 30% mobile phase B;
[0129] Time: 15 min, 70% mobile phase A, 30% mobile phase B;
[0130] Time: 16 min, 0% mobile phase A, 100% mobile phase B;
[0131] Time: 35 min, 0% mobile phase A, 100% mobile phase B;
[0132] Time: 36 min, 70% mobile phase A, 30% mobile phase B;
[0133] Time: 45 min, 70% mobile phase A, 30% mobile phase B.
[0134] Detection method: Accurately measure the reference solution, test solution and test spiked solution and inject them into the high performance liquid chromatograph for detection. The results are shown in Table 3.
[0135] Table 3. Precision test results
[0136] Sample No. Recovery rate of impurity A 1-1# 105.9% 1-2# 117.9% 1-3# 118.1% 1-4# 110.2% 1-5# 105.5% 1-6# 107.9% average value 110.9% RSD 5.1%
[0137] As shown in Table 3, the average recovery rate of impurity A in 6 test sample spiked solutions was 110.9%, RSD=5.1%, and the method had good repeatability, indicating that the precision of tryptophan impurity A was good under the chromatographic conditions of the present invention.
[0138] Example 4: Durability Test
[0139] A method for detecting tryptophan impurity A in a compound amino acid injection, comprising:
[0140] Reference substance stock solution: Take about 10 mg of tryptophan impurity A reference substance, accurately weigh, place in a 100 mL volumetric flask, dissolve with methanol-water (20:80), dilute to the scale, shake well, accurately measure 1 mL into a 100 mL volumetric flask, dilute to the scale with methanol-water (20:80), shake well, accurately measure 1 mL into a 10 mL volumetric flask, dilute to the scale with methanol-water (20:80), shake well.
[0141] Reference substance solution: Accurately measure 1 mL of reference substance stock solution, place it in the same 10 mL volumetric flask, dilute to the mark with methanol-water (20:80), and shake well.
[0142] Test solution: Accurately measure 8 mL of the product, place it in a 10 mL volumetric flask, dilute to the scale with methanol-water (20:80), shake well, and obtain.
[0143] Test sample spike solution: Accurately measure 8 mL of the product and place it in a 10 mL volumetric flask. Add 1 mL of the reference stock solution and dilute to the mark with methanol-water (20:80) and shake well.
[0144] Chromatographic conditions:
[0145] Column: kromasil Eternity-5-PhenylHexyl, 4.6 mm × 250 mm, 5 μm;
[0146] Mobile phase A: 0.02 mol / L potassium dihydrogen phosphate buffer (pH adjusted to 4.3 with phosphoric acid)-methanol (92:8);
[0147] Mobile phase B: acetonitrile-water (50:50);
[0148] Diluent: methanol-water (20:80);
[0149] Wavelength: 220nm;
[0150] Column temperature: 35°C;
[0151] Flow rate: 0.7 mL / min;
[0152] Injection volume: 100 μL;
[0153] The gradient elution conditions were as follows:
[0154] Time: 0 min, 70% mobile phase A, 30% mobile phase B;
[0155] Time: 15 min, 70% mobile phase A, 30% mobile phase B;
[0156] Time: 16 min, 0% mobile phase A, 100% mobile phase B;
[0157] Time: 35 min, 0% mobile phase A, 100% mobile phase B;
[0158] Time: 36 min, 70% mobile phase A, 30% mobile phase B;
[0159] Time: 45 min, 70% mobile phase A, 30% mobile phase B.
[0160] The durability of impurity A was investigated by changing the column temperature, flow rate and wavelength. The setting conditions of column temperature, flow rate and wavelength are shown in Table 4.
[0161] Table 4. Durability condition parameters
[0162] condition Column temperature ℃ Flow rate mL / min Wavelength nm Control 1-1a 30 0.7 220 Control 1-1b 40 0.7 220 Control 1-2a 35 0.6 220 Control 1-2b 35 0.8 220 Control 1-3a 35 0.7 200 Control 1-3b 35 0.7 230
[0163] Detection method: Set the durability condition parameters according to Table 4, accurately measure the reference solution, test solution and test spiked solution and perform detection on a high performance liquid chromatograph. The results are shown in Table 5.
[0164] Table 5. Durability test results
[0165]
[0166]
[0167] As shown in Table 5, after fine-tuning the chromatographic conditions, the recoveries of the spiked solutions of the test samples were all between 100% and 110%, and the RSD of impurity A was 6.7%, indicating that the impurity A method has good durability under the chromatographic conditions of the present invention.
[0168] From the investigation results of Example 4, it can be seen that:
[0169] In the column temperature investigation, the recovery rate was normal at 30℃ and 40℃. Combined with the column temperature durability screening results, the column temperature range of 30~40℃ was selected.
[0170] In the flow rate investigation, the recovery rates at flow rates of 0.6ml / min and 0.8ml / min were normal, and the recovery rate at 0.7ml / min was good under normal conditions. Combined with the flow rate durability screening results, the flow rate range was selected to be 0.6ml / min to 0.8ml / min.
[0171] In the wavelength investigation, the recovery rates of wavelengths 200nm and 230nm were normal, and the recovery rate of 220nm was good under normal conditions. Combined with the wavelength durability screening results, the wavelength range of 200nm to 230nm was selected.
[0172] In summary, the present invention effectively improves the separation degree of tryptophan impurity A and realizes accurate quantitative detection of the impurity by screening and optimizing the chromatographic conditions such as the mobile phase ratio, flow rate, and column temperature. The detection method has been verified by systematic methodology and has the advantages of strong specificity, high sensitivity, good precision, and strong durability. It can qualitatively or quantitatively detect the tryptophan impurity A in the compound amino acid injection, thereby improving the safety of related products.
[0173] Comparative Example 1
[0174] The difference between this comparative example and Example 1 is that the mobile phase A is 0.02 mol / L potassium dihydrogen phosphate buffer (the pH value is adjusted to 4.3 with phosphoric acid) and does not contain methanol.
[0175] The HPLC schematic diagram of the obtained system suitability solution is as follows: Figure 4 As shown, compared with Example 1, the peak shape is poor, the chromatographic peak shape is asymmetric, the tailing is more obvious, and the peak shape is wider. It can be seen that adding an appropriate amount of methanol to mobile phase A can keep the peak shape of impurity A better.
[0176] The specific implementation methods described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific implementation method of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A method for detecting tryptophan impurity A in a compound amino acid injection, characterized in that: The tryptophan impurity A in the compound amino acid injection was detected by high performance liquid chromatography, using a chromatographic column filled with phenylsilane bonded silica gel, gradient elution with a mobile phase, and detection with an ultraviolet detector; The mobile phase consists of mobile phase A and mobile phase B, wherein mobile phase A is a mixed solution of methanol and phosphate buffer solution; mobile phase B is an acetonitrile aqueous solution.
2. The method for detecting tryptophan impurity A in a compound amino acid injection according to claim 1, characterized in that: The mobile phase A is a mixed solution of methanol and a phosphate buffer solution with a concentration of 0.01 mol / L to 0.03 mol / L.
3. The method for detecting tryptophan impurity A in a compound amino acid injection according to claim 1, characterized in that: The phosphate in the phosphate buffer solution in the mobile phase A includes sodium dihydrogen phosphate and / or potassium dihydrogen phosphate.
4. The method for detecting tryptophan impurity A in a compound amino acid injection according to claim 1, characterized in that: The volume ratio of the phosphate buffer solution to methanol in the mobile phase A is (90:10) to (95:5).
5. The method for detecting tryptophan impurity A in a compound amino acid injection according to claim 1, characterized in that: The pH range of the mobile phase A is 4.0-4.
5.
6. The method for detecting tryptophan impurity A in a compound amino acid injection according to claim 1, characterized in that: The volume ratio of acetonitrile to water in the mobile phase B is (40:60) to (60:40).
7. The method for detecting tryptophan impurity A in a compound amino acid injection according to claim 1, characterized in that: The chromatographic conditions are as follows: detection wavelength of 200 nm to 230 nm, mobile phase flow rate of 0.6 mL / min to 0.8 mL / min, injection volume of 50 μL to 150 μL, and column temperature of 30° C. to 40° C.
8. The method for detecting tryptophan impurity A in a compound amino acid injection according to claim 1, characterized in that: The detection wavelength was 220 nm, the mobile phase flow rate was 0.7 mL / min, the injection volume was 100 μL, and the column temperature was 35° C.
9. The method for detecting tryptophan impurity A in a compound amino acid injection according to claim 1, characterized in that: The conditions of the gradient elution are: Time: 0 min, 68-72% mobile phase A, 28-32% mobile phase B; Time: 15 min, 68-72% mobile phase A, 28-32% mobile phase B; Time: 16 min, 0-2% mobile phase A, 98-100% mobile phase B; Time: 35 min, 0-2% mobile phase A, 98-100% mobile phase B; Time: 36 min, 68-72% mobile phase A, 28-32% mobile phase B; Time: 45 min, 68-72% mobile phase A, 28-32% mobile phase B.
10. Use of the detection method according to any one of claims 1 to 9 in detecting tryptophan impurity A in compound amino acid injection.
